Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25025814 | 0.87 | PNMT (0.47) | CYP1A2CYP11B1CYP11B2TRPV1 | |
| SCHEMBL11142645 | 0.82 | CHRNB2 (0.46) | TRPV1KIF11TDP2ADRB1ADRB3 | |
| SCHEMBL6938397 | 0.81 | CYP1A2 (0.68) | CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL11146018 | 0.78 | KIF11 (0.42) | CYP1A2CYP11B1CYP11B2KIF11TDP2 | |
| SCHEMBL9729442 | 0.77 | CYP11B1 (0.43) | CYP11B1CYP11B2TDP2 | |
| SCHEMBL11145218 | 0.76 | ADRB1 (0.40) | CYP1A2CYP11B1CYP11B2KIF11TDP2 | |
| SCHEMBL11143472 | 0.74 | CYP3A4 (0.46) | KIF11TDP2ADRB1ADRB3CHRNB2 | |
| SCHEMBL11141750 | 0.73 | CYP3A4 (0.50) | KIF11TDP2ADRB1ADRB3CHRNB2 | |
| SCHEMBL25025870 | 0.73 | PNMT (0.53) | TDP2CHRNB2CHRNA4 | |
| SCHEMBL11135536 | 0.72 | CYP3A4 (0.52) | KIF11TDP2ADRB1ADRB3CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | claimed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | CYP1A2 4367/4885CYP11B1 780/4885CYP11B2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.